Why the study?
Although oral anticoagulants are recommended for stroke prevention in AF patients at high thromboembolic risk, not all qualifying patients receive them.
This review emphasizes that while OAC use in high-risk AF patients has improved, under-prescription persists largely due to bleeding risk concerns in patients with complex comorbidities, where NOACs may offer a favorable safety profile.
The CHA2DS2-VASc scale is commonly used to assess the risk of thromboembolism in patients with atrial fibrillation (AF). Oral anticoagulants are recommended for the prevention of stroke in patients with AF with a CHA2DS2-VASc score of ≥ 2 for men and ≥ 3 for women. There are known factors that have not been included in this scale, but they significantly increase the risk of thromboembolism. Not all patients with AF who are at high risk of thromboembolism receive anticoagulation therapy. This is mainly due to the contraindications to the use of drugs from this group.
No takes yet. Share an insight, caveat, or question.
Bielecka et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: